Detection of KRAS Mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer Patients

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1589-1598

  Li, Z ^a   Chen, Y ^a   Wang, D ^a   Wang, G ^a   He, L ^a   Suo, J ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Kras oncogene; Liver metastasis; Mutation; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL; GENOMIC DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHINESE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME;

EID: 84867507466     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000439     Document Type: Article

References (45)

1. Chiu BC, Ji BT, Dai Q, et al: Dietary factors and risk of colon cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2003; 12: 201 - 208.
2. Cao KJ, Ma GS, Liu YL, et al: Incidence of colorectal cancer in Guangzhou City from 2000 to 2002. Ai Zheng 2009; 28: 441 - 444 [in Chinese, English abstract].
3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 1992; 10: 896 - 903.
4. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209 - 1214.
5. Soulières D, Greer W, Magliocco AM, et al: KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol 2010; 17( suppl 1): S31 - S40.
6. ®): Colon Cancer, v. 3. Fort Washington: NCCN, 2011.
7. Lubomierski N, Plotz G, Wormek M, et al: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumours. Cancer 2005; 104: 952 - 961.
8. Wood KW, Samecki C, Roberts TM, et al: ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell 1992; 68: 1041 - 1050.
9. Wicki A, Herrmann R, Christofori G: KRAS in metastatic colorectal cancer. Swiss Med WkIy 2010; 140: wl3112.
10. Riely GJ, Marks J, Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201 - 205.
11. Capella G, Cronauer-Mitra S, Pienado MA, et al: Frequency and spectrum of mutations at codons 12 and 13 of the c-KRAS gene in human tumours. Environ Health Perspect 1991; 93: 125 131.
12. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682 - 4689.
13. Barbacid M: Ras genes. Annu Rev Biochem 1987; 56: 779 - 827.
14. Baisse B, Bouzourene H, Saraga EP, et al: Intratumour genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 2001; 93: 346 - 352.
15. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759 767.
16. Shen H, Yuan Y, Hu HG, et al: Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol 2011; 17: 809 - 816.
17. Bazan V, Migliavacca M, Zanna I, et al: Specific codon 13 KRAS mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 KRAS mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438 - 1446.
18. Conlin A, Smith G, Carey FA, et al: The prognostic significance of KRAS, p53, and APC mutations in colorectal carcinoma. Guf 2005; 54: 1283 - 1286.
19. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001; 85: 692 - 696.
20. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992 - 3995.
21. Trevisiol C, Di Fabio F, Nascimbeni R, et al: Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int J Biol Markers 2006; 21: 223
22. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, et al: Assessment of KRAS mutation: A step toward personalized medicine for patients with colorectal cancer. Cancer 2009; 115: 3609 3617.
23. Wittekind CH, Meyer HJ, Bootz F (eds): Kolon und rektum. In: TNM Klassifikation Maligner Tumouren. Heidelberg: Springer, 2005; pp 66 70.
24. Franklin WA, Haney J, Sugita M, et al: KRAS mutation: Comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 43 - 50.
25. Jhawer M, Goel S, Wilson AJ, et al: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961. (Pubitemid 351416582)
26. Brink M, de Goeij AF, Weijenberg MP, et al: K-ras oncogene mutations in sporadic colorectal cancer in the netherlands cohort study. Carcinogenesis 2003; 24: 703 - 710.
27. Al-Mulla F, Milner-White EJ, Going JJ, et al: Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 1999; 187: 433 438.
28. Hughes R, Cross AJ, Pollock JR, et al: Dosedependent effect of dietary meat on endogenous colonic N-nitrosation. Carcinogenesis 2001; 22: 199 - 202.
29. Licar A, Cerkovnik P, Ocvirk J, et al: KRAS mutations in Slovene patients with colorectal cancer: Frequency, distribution and correlation with the response to treatment. Int J Oncol 2010; 36: 1137-1144.
30. Lee WS, Baek JH, Lee JN, et al: Mutations in KRAS and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer. Int J Surg Pathol 2011; 19: 145-151.
31. Cerottini JP, Caplin S, Saraga E, et al: The type of KRAS mutation determines prognosis in colorectal cancer. Am J Surg 1998; 175: 198 202.
32. Samowitz WS, Curtin K, Schaffer D, et al: Relationship of Ki-ras mutations in colon cancers to tumour location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193 - 1197.
33. Bos JL: The ras gene family and human carcinogenesis. Mutat Res 1988; 195: 255 - 271.
34. Zlobec I, Bihl MP, Schwarb H, et al: Clinicopathological and protein characterization of BRAF- and KRAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127: 367 - 380.
35. Akkiprik M, Çelikel CA, Düşünceli F, et al: Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. Turk J Gastroenterol 2008; 19: 22 - 27.
36. Naguib A, Mitrou PN, Gay LJ, et al: Dietary, lifestyle and clinicopathological factors associated with BRAF and KRAS mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer 2010; 10: 99.
37. Breivik J, Meling GI, Spurkland A, et al: KRAS mutation in colorectal cancer: Relations to patient age, sex and tumour location. Br J Cancer 1994; 69: 367 - 371.
38. Yunxia Z, Jun C, Guanshan Z, et al: Mutations in epidermal growth factor receptor and KRAS in Chinese patients with colorectal cancer. BMC Med Genet 2010; 11: 34.
39. Cejas P, López-Gómez M, Aguayo C, et al: KRAS mutations in primary colorectal cancer tumours and related metastases: A potential role in prediction of lung metastasis. PLo5 One 2009; 4: e8199.
40. Dix BR, Robbins P, Soong R, et al: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59: 747 - 751.
41. Tórtola S, Marcuello E, González I, et al: p53 and KRAS gene mutations correlate with tumour aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17: 1375 - 1381.
42. Adjei AA: Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001; 14: 1062 - 1074.
43. Prewett M, Rockwell P, Rockwell RF, et al: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 419 - 427.
44. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374 - 379.
45. Ramos FJ, Tabernero J: K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer. Biomark Med 2008; 2: 97 - 99.